CN118382641A - 用于恢复功能失调的针对癌症和病毒感染的人t细胞和b细胞的人源化单克隆抗体 - Google Patents

用于恢复功能失调的针对癌症和病毒感染的人t细胞和b细胞的人源化单克隆抗体 Download PDF

Info

Publication number
CN118382641A
CN118382641A CN202280075524.XA CN202280075524A CN118382641A CN 118382641 A CN118382641 A CN 118382641A CN 202280075524 A CN202280075524 A CN 202280075524A CN 118382641 A CN118382641 A CN 118382641A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280075524.XA
Other languages
English (en)
Chinese (zh)
Inventor
陈志伟
周冬燕
刘利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of CN118382641A publication Critical patent/CN118382641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280075524.XA 2021-11-15 2022-11-15 用于恢复功能失调的针对癌症和病毒感染的人t细胞和b细胞的人源化单克隆抗体 Pending CN118382641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163264061P 2021-11-15 2021-11-15
US63/264,061 2021-11-15
PCT/CN2022/132000 WO2023083377A1 (en) 2021-11-15 2022-11-15 Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection

Publications (1)

Publication Number Publication Date
CN118382641A true CN118382641A (zh) 2024-07-23

Family

ID=86335085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280075524.XA Pending CN118382641A (zh) 2021-11-15 2022-11-15 用于恢复功能失调的针对癌症和病毒感染的人t细胞和b细胞的人源化单克隆抗体

Country Status (5)

Country Link
US (1) US20250002581A1 (enExample)
EP (1) EP4433508A4 (enExample)
JP (1) JP2024544562A (enExample)
CN (1) CN118382641A (enExample)
WO (1) WO2023083377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026036133A1 (en) * 2024-08-09 2026-02-12 Scineuro Therapeutics Inc. POTENT, AGGREGATE-SELECTIVE ANTI-Aβ ANTIBODIES AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161509A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
CN105950715B (zh) * 2016-04-27 2019-04-26 深圳市第三人民医院 检测δ42pd1的方法、引物及试剂盒

Also Published As

Publication number Publication date
EP4433508A1 (en) 2024-09-25
JP2024544562A (ja) 2024-12-03
EP4433508A4 (en) 2025-11-19
US20250002581A1 (en) 2025-01-02
WO2023083377A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7282401B2 (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
US20240218074A1 (en) Anti-cd73 antibody and use thereof
KR20250143360A (ko) 종양 항원을 타겟으로 하는 키메릭 항원 수용체
KR20170075778A (ko) 항-tim-3 항체
US20250017962A1 (en) Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
CN114106182B (zh) 抗tigit的抗体及其用途
US20260042862A1 (en) Composition
BR112020005671A2 (pt) anticorpos que apresentam especificidade para btn2 e usos dos mesmos
JP2023519644A (ja) Ｓｓｅａ－４結合メンバー
US20230340146A1 (en) Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
CN111518208B (zh) 抗cd47抗体及其应用
US20240374644A1 (en) Herv-k antibody therapeutics
WO2023083377A1 (en) Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection
CN113501879B (zh) 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
US20250144214A1 (en) Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
JP2025511356A (ja) Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用
JP2018024615A (ja) Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物
US20250281538A1 (en) Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
US20220162303A1 (en) Compositions and methods for cancer therapy
HK40089235A (en) Anti-cd73 antibody and use thereof
AU2024226225A1 (en) Anti-common gamma chain proteins and compositions of matter
EA052580B1 (ru) Мультиспецифические связывающие агенты против cd40 и cd137 в терапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination